Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSF1 | Q00613 | 14/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21091547 | 1.00 | HSF1 (0.53) | HSF1CYP2D6TSHRHIF1AABCB1 | |
| Arimoclomol SCHEMBL12254223 | 0.88 | HSF1 (0.54) | HSF1CYP2D6TSHRHIF1AABCB1 | |
| Arimoclomol SCHEMBL2324741 | 0.88 | HSF1 (0.54) | HSF1CYP2D6TSHRHIF1AABCB1 | |
| Arimoclomol SCHEMBL1896428 | 0.88 | HSF1 (0.54) | HSF1CYP2D6TSHRHIF1AABCB1 | |
| Arimoclomol SCHEMBL25257807 | 0.88 | HSF1 (0.54) | HSF1CYP2D6TSHRHIF1AABCB1 | |
| Arimoclomol SCHEMBL25258754 | 0.88 | HSF1 (0.54) | HSF1CYP2D6TSHRHIF1AABCB1 | |
| Arimoclomol SCHEMBL12254225 | 0.88 | HSF1 (0.54) | HSF1CYP2D6TSHRHIF1AABCB1 | |
| Arimoclomol SCHEMBL196123 | 0.88 | HSF1 (0.54) | HSF1CYP2D6TSHRHIF1AABCB1 | |
| Arimoclomol SCHEMBL5699241 | 0.88 | HSF1 (0.54) | HSF1CYP2D6TSHRHIF1AABCB1 | |
| SCHEMBL6009202 | 0.87 | HSF1 (0.65) | HSF1CYP2D6TSHRHIF1AABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024306-A1 | PROCESSES FOR PREPARING ARIMOCLOMOL CITRATE AND INTERMEDIATES THEREOF | ZEVRA DENMARK AS (DK) | 2024-01-25 | — | — | US | disclosed |
| US-11707456-B2 | Processes for preparing arimoclomol citrate and intermediates thereof | KEMPHARM DENMARK A/S | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707456-B2 | Processes for preparing arimoclomol citrate and intermediates thereof | ACLY, AURKC, AURKA | HSF1 4634/4885CYP2D6 1564/4885TSHR 4655/4885 |
| US-20240024306-A1 | PROCESSES FOR PREPARING ARIMOCLOMOL CITRATE AND INTERMEDIATES THEREOF | ACLY, AURKC, AURKA | HSF1 4634/4885CYP2D6 1564/4885TSHR 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.